Table 5.
ASF vector vaccines.
| Vaccine type | Sequence source | Gene/protein | Specific antibodies | Neutralizing antibodies | References |
|---|---|---|---|---|---|
| Vector vaccines | E75 | sHA/p54/p30 fusion | No | No | Argilaguet et al. (2013) |
| Georgia 2007/1 | p30, p54, pp62, and p72 | Yes | No | Lokhandwala et al. (2016) | |
| A151R + B119L + B602L + EP402R∆PRR + B438L + K205R + A104R | Yes | No | Lokhandwala et al. (2017) | ||
| Ad-ASFV-I: A151R, B119L, B602L, EP402R∆PRR, B438L, K205R, A104R, pp62 and p72 Ad-ASFV-II: p30, p54, pp62, p72 and pp220 (p37-34-14, p150-I and p150-II) |
Yes | / | Lokhandwala et al. (2017) | ||
| pE199L | / | / | Hübner et al. (2018) | ||
| p72 | Yes | / | Chen et al. (2016) | ||
| 35 antigens | Yes | / | Cadenas-Fernández et al. (2020) | ||
| p72, p54, p12 and p72, type Lectin (EP153R), CD2v and p72, C-type Lectin (EP153R) and CD2v |
Yes No / |
No / / |
Lopera-Madrid et al. (2017) | ||
| NCBI Virus Database | p30, pp62, p54, p72 and CD2v | Yes | / | Chen et al. (2022) | |
| p30, p54 and p72 | Yes | Yes | Murgia et al. (2019) | ||
| p32 and p54 | Yes | / | Fang et al. (2022) | ||
| HLJ/2018 | CD2v | Yes | / | Feng et al. (2020) |